Iben S.
- Country
- Denmark
- Department
- Onkologisk Afdeling
Research Overview
- A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
- A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
- Efficacy and Safety Evaluation of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic Solid Tumors Harboring HER2 Activating Mutations
Data & Insights
Has run more than one trial at 9 of 35 partner sites.
Specializations
Advanced Cancer Research
The investigator specializes in treating advanced and metastatic solid tumors, with particular emphasis on developing innovative therapeutic approaches for patients with limited treatment options.
- Metastatic Tumor Management
- Advanced Cancer Therapeutics
- Solid Tumor Treatment Strategies
Their work encompasses various tumor types and stages, focusing on comprehensive treatment approaches.
Targeted Molecular Therapy
The investigator focuses on genetic mutation-specific treatments, particularly involving HER2 mutations and KRAS G12C mutations in solid tumors.
- HER2-Expressing Cancers
- KRAS Mutation Therapies
- Molecular Targeting Strategies
Their research explores personalized treatment approaches based on specific genetic markers.
Combination Therapy Development
The investigator studies novel therapeutic combinations, including work with immunotherapy agents and targeted treatments for enhanced efficacy.
- Immunotherapy Combinations
- Multi-Drug Approaches
- Treatment Response Assessment
Their expertise includes evaluating treatment responses and optimizing combination strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.